We generate pre-screened mass tort leads for law firms in all 50 states — running our own media, screening every claimant against your written criteria, and verifying identity through LexisNexis before the lead reaches you. One lead, one firm: never resold, never recycled, never sold on later as aged leads. First leads land in your CRM in 7–10 days, and anything that misses your criteria is replaced free within 7 days.
We generate qualified claimants across the most active mass tort categories in the country. Select a tort type to learn more about our campaigns and lead quality.
GLP-1 receptor agonist claims for gastroparesis and severe GI injury, screened to the MDL 3094 diagnostic standard.
Contraceptive injection claims linked to meningioma brain tumors, with imaging confirmation captured at intake.
Occupational and secondary exposure claims with documented work history and a confirmed diagnosis.
Confirmed mesothelioma diagnosis with a traceable exposure source and an intact statute of limitations.
Chemical hair straightener claims linked to uterine cancer, ovarian cancer and endometriosis.
Ovarian cancer and mesothelioma claims tied to documented long-term talc use.
Minor exploitation and grooming claims. Phone-first intake — these cannot be qualified any other way.
Compulsive-design claims with documented behavioral, academic or clinical impact.
Adolescent mental health claims against platform design, with clinical documentation.
Running several torts at once? Most firms do. Mass tort volume follows litigation milestones, so it arrives in waves — firms often run more than one campaign at a time to keep intake staff productive between them. One account, one point of contact. If you are signing a tort that isn’t listed, ask: we monitor filings and FDA actions daily and regularly build campaigns before they get a page.
Get Pricing Across TortsPlaintiff law firms come to us for one thing: qualified mass tort leads they can actually sign. Whether you call them mass tort attorney leads, mass tort case leads or simply claimants, the test is the same — can your intake team turn them into signed cases on an MDL docket? But for every hundred people who respond to a mass tort ad — whether the tort involves a defective drug, a faulty medical device or a toxic exposure — most will never become a case. They took the wrong drug. They took it outside the injury window. Their statute of limitations expired. They already signed with another firm.
The entire job of mass tort lead generation is to filter those people out before they reach your intake team, not after. That is the whole discipline, and it is why a cheap lead and an expensive lead are usually two different products rather than two different prices.
Every mass tort campaign has three moving parts. Media is the advertising that reaches injured people — television, radio, connected TV, paid social, podcasts and search. Anyone can buy ads; the skill is matching the channel to the claimant population for each tort. Screening is the set of filters that separates real claimants from everyone else, and it is where most failed campaigns actually fail — your paralegals pay for that failure twenty minutes at a time. Delivery is getting verified claimants into your firm’s hands before they go cold, by live transfer, real-time CRM push or scheduled batch.
We do all three in-house. That is the difference between a mass tort lead generation company and a lead broker, and it is the reason we can tell you where any claimant came from.
For over 15+ years, we have been delivering exceptional results for our clients nationwide, using our in-depth understanding of complex MDL litigation marketing and claimant acquisition experience.
Our mission is to be your trusted source and reliable partner in plaintiff acquisition services focused solely on mass torts.
Qualified leads are the middle of what we do, and the rest of this page covers them in detail. If you already know you want something further down the chain — claimants signed onto your paper, or your intake desk run for you — those are separate services, and you can skip straight to them.
Building the top of the funnel yourself? See how our mass tort lead generation works →
Most companies selling mass tort leads are buying them from somebody else and marking them up. That is why the same claimant ends up at three firms, why nobody can produce a consent record when you ask, and why “exclusive” turns out to mean “not resold within thirty days.”
We buy the media ourselves — television, radio, connected TV, paid social, podcast inbounds and search — and we run the intake floor that screens what comes back. Nothing in the chain is subcontracted, which is the only reason we can tell you where a claimant came from, hand you the consent record, and stand behind the lead when your case manager reviews it.
That matters more than it used to. Under ABA Formal Opinion 501, a firm that hires a lead generator, sets no limits, and never asks how claimants were sourced is the party that violated the rules — not the vendor. You are supervising us under Model Rule 5.3 whether you asked to or not. We build the file so you can actually do that.
Our exclusive mass tort leads are exclusive in the literal sense: one lead, one firm, permanently. Not shared at delivery, not recycled later as aged leads, not in any tort at any point. Ask any vendor whether “exclusive” means never resold or merely not resold within thirty days.
Leads post to your CRM the moment they clear verification. Contact rates fall off a cliff within the first hour — we don’t let a verified claimant sit in a queue.
Wrong exposure window, prior representation, statute run out? Tell us and we replace it. No form, no restocking argument.
A spreadsheet of people who once clicked an ad is data, not leads. Every company selling mass tort legal leads works with the same three tiers whether they name them or not — and a price comparison across two different tiers tells you nothing at all.
Anyone who responded to an advertisement. No screening past a working phone number.
Cheap per unit, expensive in salaried intake hours. Most will not qualify, and you find out one call at a time.
Screened against your written criteria - injury or diagnosis confirmed, exposure window checked, statute intact, no prior representation.
Your team opens conversations with people who already fit the criteria you set at onboarding.
Retainer executed on your paper, QC-reviewed, delivered case-ready with the full file attached.
Highest price, lowest intake load. Detailed on our case acquisition page.
Mass tort lead generation lives or dies on channel selection. We run television, radio, connected TV, paid social, podcast inbounds and search — then match each tort to the media its claimant population actually uses. That is how a mass tort advertising campaign delivers qualified leads instead of wasted spend.
Different injured populations consume different media. An asbestos claimant is usually sixty-five or older and reached on radio or daytime television; a hair relaxer claimant might be thirty-five and reached on paid social. Running the wrong channel for a tort is the most expensive mistake in mass tort marketing, and it is invisible until the invoice arrives.
One team buys the media, tests the creative and screens the claimants, with transparent reporting on every dollar. Nothing is subcontracted to a broker.
Honest monthly minimums from our own campaign data. These are media minimums, not per-lead prices. Your actual cost per lead depends on the tort, its stage in the multidistrict litigation (MDL) timeline and how strict your criteria are — and cost per qualified lead is the only version of that number worth comparing between vendors. Some firms prefer a pay per lead model, others buy signed mass tort cases outright; we quote both.
| Marketing Channel | Best-Fit Tort Types | Avg. Min. Monthly Media | Why It Works |
|---|---|---|---|
| Podcast Inbounds | 3M Earplugs, GLP-1 drugs (Ozempic, Mounjaro) | $1,000 – $5,000 | Reaches engaged younger and working-age claimants at the lowest entry cost of any channel. |
| Radio Inbounds | Bard PowerPort, Asbestos | $2,000 – $10,000+ | Reaches elderly and rural claimant populations that digital channels systematically miss. |
| Social Media Ads | Roundup, GLP-1 drugs, CPAP (Philips recall) | $2,500 – $5,000 | Precise demographic targeting with fast creative iteration and same-day performance data. |
| CTV Inbound Calls | Talcum Powder, Hair Relaxer, Camp Lejeune | $5,000 – $15,000 | Television-grade reach on Hulu and Roku with digital-grade tracking on every impression. |
| Pay Per Click (PPC) | Mesothelioma, high-intent single-tort searches | $5,000 – $25,000 | Captures claimants already searching. Highest intent, highest cost per click in legal. |
| Television Ads | CPAP (Philips recall), Asbestos | $10,000 – $50,000+ | Largest addressable reach for older claimant pools; needs volume to amortise production. |
| Live Call Transfers | Any tort where intake speed decides conversion | Priced per transfer | Claimant is on the phone with your intake agent while still motivated. No callback decay. |
A campaign is almost never one channel. The mix changes by tort, and we rebalance it as cost per qualified lead moves.
Qualified mass tort leads are what comes out of four screens, not what goes into them. Every inbound contact narrows through all four, and what reaches your CRM is what survived.
Your qualification rules become a signed document before a dollar of media runs. It is what the replacement guarantee is measured against.
Every inbound contact is risk-scored before a human picks up, then identity-matched through LexisNexis.
A trained agent asks the questions that decide whether the case is filable. Agents are paid on whether a claimant survives your review, never on volume.
The claimant posts to your CRM the moment they clear, with the evidence trail attached and retrievable years later.
Most campaigns that fail don’t fail at media. They fail at layers two and three, and the buying firm pays for it in intake hours rather than in a visible line on an invoice.
Mass tort intake is the process of screening, verifying and qualifying potential plaintiffs before they reach your attorneys. Our mass tort call center runs 24/7/365 and covers claimants in all 50 states. It is also where nearly every vendor relationship quietly breaks: if intake agents are paid per lead transferred, marginal claimants get waved through by design, and your firm buys somebody’s bonus.
Our intake agents are never compensated on volume. They are rewarded for qualified, case-ready claimants, which is the only compensation structure that survives contact with a tight criteria sheet. Our specialists screen across every active campaign — Ozempic, Depo-Provera, Talcum Powder, Hair Relaxer, Mesothelioma, Asbestos and the rest — against the criteria you set, not a generic script.
You can buy qualified mass tort leads and keep intake in-house, or hand us the calling, qualifying and document chasing entirely. Most firms start with the former and move to the latter once volume outruns their paralegals.
Non-Incentivised Agents
No per-transfer bonus, no volume quota. Agents are measured on how many delivered claimants your firm actually signs, which is the only number that aligns us.
Verified Plaintiff Services
LexisNexis identity verification on SSN, address and date of birth, plus background and dark-web scans, before a claimant is transferred to your firm.
24/7/365 Coverage, Bilingual
Claimants respond to advertising at night and at weekends. An intake desk that closes at five converts a fraction of what an always-on one does.
Criteria That Sharpen Over Time
We track lead-to-signed conversion by criterion and tighten the screen as feedback arrives, so the same lead volume yields more signed cases each month.
Straight Into Your Case Management System
Our Leverage Automation layer bridges signed retainers into your CMS without rekeying, removing both the delay and the transcription errors that come with it.
Mass tort advertising sits inside a web of rules — TCPA on outreach, HIPAA on health information, state bar rules on legal advertising, plus CCPA and GDPR on data handling. This is not a badge for the footer. Non-compliant lead generation creates real exposure for the law firm that buys the leads, not only for the vendor that generated them.
If a claimant was robocalled without consent, that consent problem travels with the lead into your file. Our consent records, call recordings and data trails exist so that never becomes your problem. Every lead we deliver carries its own paper trail: form language, timestamp, IP address, page URL and call recording.
TCPA
HIPAA
ABA
CCPA
GDPR
Cost per qualified lead swings by multiples across a single litigation’s life. Nothing about the claimants changes. The competition does. We track JPML filings, FDA actions and bellwether outcomes monthly — and we will tell you when a tort has become too expensive for your economics, including when saying so costs us the sale.
Stage One
A fresh FDA action, a new docket, or claims still moving through state court before consolidation. Awareness is low, competition is light, and cost per qualified lead sits at its floor. The trade-off is that the litigation’s trajectory is not yet proven.
Stage Two
The MDL is consolidated and discovery is underway. Qualifying criteria are settled, creative is proven, and campaigns run efficiently against a known standard. The sweet spot for most firms building a docket.
Stage Three
Settlement talk is circulating and the claimant pool is shrinking while every firm in the country advertises against it. Still worth entering if your docket economics support the price — but only then.
Where Our Campaigns Sit Today
205,540 claims pending across 162 active federal MDLs
Source: JPML, Distribution of Pending MDL Dockets by Actions Pending
Report dated 3 August 2026 · updated monthly
Asbestos and mesothelioma sit outside this table on purpose. Those claims run overwhelmingly through state courts and bankruptcy trusts rather than the federal MDL system, so pending-action counts understate them badly. We price them off trust filing volume and diagnosis rates instead. Ask and we’ll walk you through the difference.
Whether you work with us or with someone else, ask any of the mass tort lead generation companies and mass tort marketing companies you are considering these six questions before you sign. We win on all six, which is why we are happy to put them on our own page. Most firms comparing mass tort lead generation services never get past price per lead, and that is exactly the number that tells you the least.
Shared leads are sold to three to eight firms at once. Contact rates collapse and your intake team races competitors to the phone. Ask for the answer in writing, and ask specifically whether “exclusive” means never resold, or merely not resold within thirty days. Those are very different products at very similar prices.
Raw responses, qualified leads or signed retainers — the price per unit means nothing without this. A vendor quoting eighty dollars a lead is almost always selling raw responses. That is not a better price; it is a different product, and the screening work simply moves onto your payroll.
If agents earn per lead transferred, the screening is compromised by design. Marginal claimants get waved through and you fund the bonus. Ask how compensation is structured before you ask anything about price.
A vendor with no replacement guarantee is telling you they do not stand behind their own qualification. Ours is seven days, free, measured against the written criteria sheet agreed before any media ran — no restocking argument and no form to fight through.
TCPA consent documentation should exist for every single lead and be available to you on request. If a vendor hesitates, walk. Under ABA Formal Opinion 501, a firm that hires a lead generator, sets no limits and never asks how claimants were sourced is the party that violated the rules.
A good partner will tell you when a tort has gone too late-stage and expensive to enter, even when saying so costs them the sale. A lead reseller never will. Fifteen years in this industry taught us that a firm which overpays once does not come back.
From planning and campaign design through to intake and acquisition, these are the practices that separate a mass tort campaign that builds a docket from one that builds an invoice. They apply whether you run the campaign yourself or hire someone to run it.
Lead acquisition is the campaign’s ultimate goal, so begin with the psychology and circumstances of the claimant you want. Age, media habits, treatment history and geography all change which channel reaches them and what the lead will cost. Every campaign we build starts with a consultation, not an ad.
Diagnosis, usage or exposure window, treatment history, state restrictions and statute status all belong on a signed criteria sheet before a dollar is spent. Criteria drive cost: a firm accepting any Ozempic user with gastroparesis symptoms pays far less per lead than one requiring a confirmed diagnosis plus hospitalisation records. Neither is wrong, but the campaign has to be built for it from day one.
Selecting media by what is cheapest this quarter is the fastest way to burn a mass tort marketing budget. An asbestos claimant and a hair relaxer claimant are thirty years apart and consume completely different media. Pick the channel the population actually uses, then negotiate the rate.
Speed to first contact is the single largest lever on lead-to-signed conversion, and it is almost entirely within your control. Industry-wide, lead-to-signed conversion runs roughly five to twenty-five percent; the spread is explained more by response time and criteria discipline than by lead source.
Form language, timestamp, IP address, page URL and call recording should travel with every claimant into your file. In TCPA litigation the fight is almost never about which rule applied; it is about whether you can produce the record two years later.
Track lead-to-signed conversion by individual criterion, not just in aggregate, and tighten the screen where the losses concentrate. Done consistently, the same monthly lead volume produces more signed cases each quarter without any increase in media spend.
Leads that sit uncalled convert at a fraction of the rate, so buying more than your desk can work destroys spend faster than any pricing mistake. We slow campaigns rather than let leads go cold, and if the bottleneck is structural we can take intake over entirely.
FDA warnings, MDL consolidation and bellwether verdicts each move cost per qualified lead sharply. Entering a late-stage tort without clear docket economics is the most common way firms lose money on mass tort marketing that was executed perfectly otherwise.
No long-term contract, no minimum buried in the fine print.
Step 01
Tell us the litigation, the diagnosis or exposure requirements, geography, and monthly volume. We write it down — that document becomes what your replacement guarantee is measured against.
Step 02
Price depends on the tort, how strict your criteria are, and whether you want qualified leads or signed retainers. You get a real number for your campaign, not a range that fits nobody.
Step 03
Verified claimants start posting to your CRM within 7–10 days of setup on an active tort. Two to three weeks if we’re building a campaign from scratch. Anything off-criteria is replaced free within 7 days.
Every vendor selling mass tort leads describes itself the same way. These are the three commitments we put in the campaign agreement instead — each one checkable, each one something you can hold us to.
Fifteen-plus years of campaign data across every major MDL of that period. That archive is the only reason we can price a brand-new tort with any confidence — we already know what the claimant population costs to reach, which channel answers the phone, and how fast the number moves once a docket consolidates. A vendor without that history is quoting you a guess.
One lead, one firm. Not shared at delivery, and not resold later as aged inventory once the campaign closes — which is the loophole most “exclusive” contracts leave open. Read the definition in any competing quote carefully: some vendors define exclusive as “not sold twice within thirty days.” Ours has no clock on it.
Wrong exposure window, prior representation, statute already run? Tell us and we replace it at no cost. Replacement is measured against the written criteria sheet we build with your case managers before any media runs — not against a conversation someone half-remembers. That is precisely why we insist on getting the criteria document painfully specific rather than agreeable.
Partners who have run mass tort campaigns with us, in their own words.
Injury Case Claims have consistently exceeded our expectations with the highest quality of service and quality of case leads we have seen in a long time. It is my opinion and experience that quality is not cheap, it is PRICELESS when you build your docket.
The team at ICC have an eye for details that even my own paralegals have not established. To work with an all-in-one company is a blessing in disguise because their pro plan has unlocked a ton of time for my staff and myself. The money is well worth the transparency and added value in services received.
We have been doing mass torts for 21 years and have worked with quite a few marketing companies, but when we got onboard with Injury Case Claims we knew this was going to be a different experience from day one. They truly offer excellent communications throughout each step of the onboarding process, with quality of cases superb.
I have worked with Injury Case Claims on several campaigns for which my experience has been nothing short of great. Thanks and keep up the good work so we can be partners for many years to come.
Tell us the litigation and the criteria your case managers actually use. We’ll come back with real numbers, a delivery timeline, and an honest read on whether that tort’s economics justify the spend right now. If they don’t, we’ll say so.
Looking for mass tort claimants for your docket? Tell us what you’re signing and we’ll respond within 24 hours with next steps and pricing.
By submitting, you consent to be contacted by InjuryCaseClaims.com regarding your inquiry. This does not constitute a binding agreement. All information is handled securely and confidentially.
Straight answers to what firms want to know before buying mass tort leads or signed cases from us. Anything not covered here, call and ask.